Drug-induced liver injury
Drug-induced liver injury
6
Drug-induced liver injury: the dawn of biomarkers?
16
Chemical and biochemical aspects of drug-induced liver injury
205
The diagnosis and management of idiosyncratic drug‐induced liver injury
11
Mechanistic regulation of HMGB1 function in drug-induced liver injury
228
New approaches to improve prediction of drug-induced liver injury
212
Immune-Mediated Drug Induced Liver Injury: A Multidisciplinary Approach
446
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
48
Role of hepatic transport proteins in drug disposition and drug-induced liver injury
256
Drug-induced liver injury: Interactions between drug properties and host factors
12
Death and liver transplantation within 2 years of onset of drug‐induced liver injury
11
Death and Liver Transplantation within Two Years of Onset of Drug-Induced Liver Injury
28
Clinical factors predicting drug-induced liver injury due to flucloxacillin
7
Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation
28
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury
12
Investigating the role of reactive metabolites and parent compound in drug induced liver injury
208
Investigating the role of reactive metabolites and parent compound in drug induced liver injury
208
Matrix factorization-based data fusion for drug-induced liver injury prediction
5
Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase
7
Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury
5